According to Dr. Carl Fuhrman of UPMC Radiology, "The concept of 'personalized medicine' is at the forefront of current medical practice with medical decisions and treatment being tailored to the individual patient. In radiology, the descriptive terminology regarding chronic obstructive pulmonary disease, such as 'mild' or 'moderate,' are no longer acceptable to accurately assess disease. Imbio allows for accurate and reproducible quantitative measurements of COPD, providing more specific measurement of disease severity and progression over serial examinations, which is crucial to our mission of personalized medicine."
The UCA platform for imaging analytics has begun the journey of building out a broad range of machine vision and artificial intelligence tools that will enable imaging diagnosticians in radiology, cardiology and oncology to profoundly increase their insights with tools that are independent of picture archive and communication system applications but are integrated into the reporting process. The result is a greater quality and value brought from enhancing the level of detailed analysis that can be quantitatively used to help understand the anatomical imaging. These results can be used in driving patient segmentation for risk and assessing the impact of care pathways to drive more personalized individual care decisions, as well as radiology's participation in population health.
"We're extremely pleased to expand our cloud offerings and look forward to Imbio's insights into emerging tools that will help our clients accelerate patient care and engagement, while also participating in driving the value of medical imaging," said Dan Allison, president, Global Healthcare and Life Sciences, NTT DATA Services.
A demonstration of this tool and other analytics is available in the Imbio booth #6647 at RSNA 2016 and the NTT DATA Services booth #2504.
Imbio is transforming medical image analysis by making breakthrough Radiology diagnostics affordable and accessible for all physicians. Imbio's software-based products generate personalized, quantitative patient information from standard imaging data, enabling radiologist to more accurately diagnose complex diseases and track treatment response. All of Imbio's commercially available products are FDA and/or CE approved and are fully automated, eliminating the requirement to learn new software or perform any additional steps to obtain results. With flexible Cloud and On-Premise SaaS solutions, Imbio makes advanced image analysis accessible to all healthcare providers directly and through strategic partners. Imbio's commercially available Lung Density Analysis™ and Lung Texture Analysis™ are part of the company's pulmonary portfolio supporting the diagnosis and care of chronic lung conditions. For more information, please visit www.imbio.com.
About NTT DATA
NTT DATA partners with clients to navigate the modern complexities of business and technology, delivering the insights, solutions and outcomes that matter most. We deliver tangible business results by combining deep industry expertise with applied innovations in digital, cloud and automation across a comprehensive portfolio of consulting, applications, infrastructure and business process services. NTT DATA is a top 10 global business and IT services provider with 100,000+ professionals in more than 50 countries, and is part of NTT Group, a partner to 85 percent of the Fortune 100.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/imbio-and-ntt-data-services-announce-partnership-for-lung-analytic-algorithms-in-the-uca-imaging-platform-300371079.html